Evidence map›Paper›PMID 38928352›Full record

ArticleInternational journal of molecular sciences2024

An Antibody of the Secreted Isoform of Disintegrin and Metalloprotease 9 (sADAM9) Inhibits Epithelial-Mesenchymal Transition and Migration of Prostate Cancer Cell Lines.

Yura Jotatsu, Shain-Ying Sung, Ming-Heng Wu, Shunya Takeda, Yuto Hirata, Koki Maeda, Shiuh-Bin Fang, Kuan-Chou Chen, Katsumi Shigemura

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yura JotatsuDepartment of Public Health, Kobe University Graduate School of Health Sciences, 7-10-2 Tomogaoka, Suma-ku, Kobe 654-0142, Japan.
Shain-Ying SungInternational Ph.D. Program for Translational Medicine, College of Medical Sciences and Technology, Taipei Medical University, Taipei 11031, Taiwan.ORCID 0000-0002-0078-3899
Ming-Heng WuInternational Ph.D. Program for Translational Medicine, College of Medical Sciences and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Shunya TakedaDepartment of Medical Device Engineering, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.
Yuto HirataDepartment of Public Health, Kobe University Graduate School of Health Sciences, 7-10-2 Tomogaoka, Suma-ku, Kobe 654-0142, Japan.ORCID 0009-0001-7065-7003
Koki MaedaDepartment of Urology, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.ORCID 0000-0001-5027-3822
Shiuh-Bin FangDivision of Pediatric Gastroenterology and Hepatology, Department of Pediatrics, Shuang Ho Hospital, Taipei Medical University, 291 Jhong Jheng Road, Jhong Ho District, New Taipei City 23561, Taiwan.ORCID 0000-0003-2742-8886
Kuan-Chou ChenDepartment of Urology, Taipei Medical University Shuang Ho Hospital, 291, Zhongzheng Road, Taipei 235, Taiwan.ORCID 0000-0001-5512-4631
Katsumi ShigemuraDepartment of Urology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan.ORCID 0000-0002-5695-2794

Funding

kakenhi 23KK0158
6 · The paper itself

Abstract

Prostate cancer (PC) is the most common cancer diagnosed in men worldwide. Currently, castration-resistant prostate cancer (CRPC), which is resistant to androgen deprivation therapy, has a poor prognosis and is a therapeutic problem. We investigated the antitumor effects on PC of an antibody neutralizing secreted disintegrin and metalloproteinase domain-containing protein 9 (sADAM9), which is a blood-soluble form. We performed proliferation assays, wound healing assays, invasion assays, Western blot (WB), and an in vivo study in which a sADAM9 neutralizing antibody was administered intratumorally to PC-bearing mice. In invasion assays, the sADAM9 neutralizing antibody significantly inhibited invasion in all cell lines (TRAMP-C2:

Indexed as

ADAM ProteinsCell MovementEpithelial-Mesenchymal TransitionProstatic NeoplasmsAnimalsAntibodies, NeutralizingCell Line, TumorCell ProliferationHumansMaleMembrane ProteinsMiceXenograft Model Antitumor AssaysADAM9 protein, humanADAM ProteinsAntibodies, NeutralizingMembrane ProteinsADAM9castration-resistant prostate cancerepithelial–mesenchymal transition (EMT)invasionsecreted ADAM9

Identifiers

PMID38928352
PMCPMC11203924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.